Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?

Stavros Apostolakis; Gregory Y. H. Lip

doi:10.1160/TH11-08-0580

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(05): 753-754
DOI: 10.1160/TH11-08-0580

Invited Editorial Focus

Schattauer GmbH

Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?

Authors

Stavros Apostolakis

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
Gregory Y. H. Lip

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

Abstract

PDF Download

PDF (64 kb)

References

References
1 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
2 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
3 Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?. Thromb Haemost 2010; 104: 45-48.
4 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011; 106: 739-751.
5 Apostolakis S, Shantsila E, Lip GY. et al. Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”. Thromb Haemost 2009; 102: 914-915.
6 Odén A, Fahlén M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117: 493-499.
7 Lane DA, Lip GY. Anticoagulation intensity for elderly atrial fibrillation patients: should we use a conventional INR target (2.0 to 3.0) or a lower range?. Thromb Haemost 2010; 103: 254-256.
8 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
9 Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematology 2004; 126: 557-564.
10 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010; 104: 49-60.
11 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578.
12 Gallagher A, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
13 Connolly SJ, Pogue J, Eikelboom J. et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
14 Reynolds MW, Fahrbach K, Hauch O. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126: 1938-1945.
15 Tay KH, Lip GY, Lane DA. Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb Haemost 2009; 101: 415-416.
16 Aspinall SL, Zhao X, Handler SM. et al. The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. J Am Geriatr Soc 2010; 58: 1475-1480.
17 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
18 Wieloch M, Själander A, Frykman V. et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011. epub ahead of print
19 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.